REFERENCES
- Bruchovsky N, Lesser B, Van Doom E. Hormonal effects on cell proliferation in rat prostate. Vitamin Horm 1975; 33: 61–102.
- Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. The Prostate 1987; 11: 41–50.
- Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, LeRichie JC, Murray NC. The endocrinology and treatment of prostate tumour progression. In: Coffey DS, Bruchovsky N, Gardner WA Jr, Resnick MI, Karr JP, eds. Current concepts and approaches to the study of prostate cancer: progress in clinical and biological research. New York: Alan R Liss Inc., 1987; 239: 348–87.
- Schultze H, Oesterling JE, Isaacs JT, Coffey DS. Hormonal therapy of prostate cancer: limitations in the total androgen ablation concept. In: Coffey DS, Resnick MI, Don FA, Karr JP, eds. A multidisciplinary analysis of controversies in the management of prostate cancer. New York: Plenun Press, 1988: 215–24.
- Krieg M, Tunn S. Pathological aspects of the malignant and benign growth of the human prostate. In: Aumuller G, Krieg M, Senge T, eds. New aspects in the regulation of prostatic function. Munich: W Zuckschwerdt Verlag, 1989: 3–12.
- Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate specific antigen. Cancer 1993; 71: 2782–90.
- Isaacs JT. The timing of androgen ablation therapy and/ or chemotherapy in the treatment of prostatic cancer. The Prostate 1984; 5: 1.
- Coffey DS, Isaacs JT. Prostate tumour biology and cell kinetics theory. Urology 1981; 27 Suppl 3: 40.
- Isaac JT, Kyprianou N. Development of androgen independent tumour cells and their implication for the treatment of prostatic cancer. Urol Res 1987; 15: 133.
- Noble RL. Hormonal control of growth and progression in tumours of Nb rates and a theory of action. Cancer Res 1977; 37: 82.
- Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. The effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275.
- Furuya Y, Sato N, Akakura K. Paracrine growth stimulation of androgen responsive Shionogi carcinoma 115 by its autonomous subline (Chiba Subline 2). Cancer Res 1990; 50: 4979.
- Bruchovsky N. Androgens and antiandrogens. In: Kufe DW, Morton DL, Weichselbaum RR, et al. Cancer medicine, 3rd edn. (Holland JF, Frei III E, Bast RC, eds). Philadelphia: Lea & Febiger, 1993: 884–96.
- Klotz LH, Herr HW, Morse MJ, Whitmore WF. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546.
- Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer. A preliminary report. Urology 1995; 45: 839–45.
- Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Maximal biochemical and pathological downstaging requires 8 months of neoadjuvant hormo-nal therapy prior to radical prostatectomy. J Urol 1995; 153: 392A.
- Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800–4.
- Oliver RT, Williams G, Paris AM, Blandy JP. Intermittent androgen deprivation after PSA—complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997; 49: 79–82.
- Grossfield GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51: 137–44.
- Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992; 147: 956–61.
- Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience. Eur Urol 1998; 34 Suppl 3: 37–41.